Source: Pharmabiz

Ventus: Ventus Therapeutics' partner Novo Nordisk doses first participant in phase 1 clinical study for NNC60220001, an oral NLRP3 inhibitor

Ventus Therapeutics, Inc, a clinical─stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE, to develop differentiated small molecule

Read full article »

Ventus's Competitors | Ventus's News | Ventus's Financials

Followers on Owler

Est. Annual Revenue

$25-100M

Est. Employees

25-100

President & CEO

Marcelo Bigal

CEO Approval Rating

90/100

Ventus is a Canada-based biopharmaceutical company that develops and commercializes small-molecule drugs to treat diseases including autoimmune and inflammatory.